Desmethylselegiline - RetinaPharma Technologies

Drug Profile

Desmethylselegiline - RetinaPharma Technologies

Alternative Names: ApoGuard; DES; Desmethyldeprenyl; Neurap; RT-001 - RetinaPharma

Latest Information Update: 20 Jan 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RetinaPharma Technologies; University of Toronto Innovations Foundation
  • Class Antiparkinsonians; Phenethylamines; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Age-related macular degeneration; Neurological disorders

Most Recent Events

  • 17 Jan 2005 Desmethylselegiline is available for licensing (http://www.retinapharma.com)
  • 21 Jan 2004 Preclinical trials in Age-related macular degeneration in USA (Unknown route)
  • 21 Jan 2004 Preclinical trials in Neurological disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top